Jad Chahoud, Medical Director of IPOP and Associate Member of the Department of Genitourinary Oncology at Moffitt Cancer Center, shared a post on LinkedIn:
“Practice-Informing Data in 2L mccRCC | ESMO 2025 Oral Presentation + Annals of Oncology
For the first time, two contemporary second-line options after PD-1–based immunotherapy in metastatic clear cell RCC (mccRCC) have been compared head-to-head:
Lenvatinib + everolimus vs. cabozantinib
LenCabo Phase II Trial Oral presentation at ESMO25
Simultaneous publication in Annals of Oncology
full manuscrip.
Key Findings
• Median PFS: 15.7 vs 10.2 months (HR 0.51, p = 0.02)
• ORR: 52.6% vs 38.6%
• 1-year OS: 87.0% vs 84.6% (immature)
• Toxicity-related discontinuations: 20% vs 10.9%
Takeaway:
Lenvatinib + everolimus significantly prolonged PFS compared to cabozantinib following progression on PD-1–based ICI combinations.
Proud to be part of the first head-to-head evidence to inform treatment sequencing in the post–IO setting for mccRCC.”
Title: A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
Authors: A.W. Hahn, J. Chahoud, W.P. Skelton, Y. Yuan, A.J. Zurita, C. Kovitz, O. Alhalabi, M.T. Campbell, E. Jonasch, J. Lin, M. Desai, M.J.M.N. Santos, H. Hwang, P.G. Corn, P. Msaouel, N.M. Tannir
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
